29 Results for "

structure-based design

" in MedChemExpress (MCE) Product Catalog:
Products (29)

29 Results for "structure-based design" in MCE Product Catalog:

Cat. No.: HY-157310
CAS No.: 2735015-52-6
Target:  

Tau Protein

Research Areas:  

Neurological Disease

TTBK1-IN-3 (Compound 18) is a potent inhibitor of TTBK1, with a biochemical IC₅₀ of 18 nM and a cellular IC₅₀ of 259 nM. TTBK1-IN-3 can be used for research on Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-179721
CAS No.: 923714-61-8
Research Areas:  

Neurological Disease

CCKBR agonist-2 (Compound z-44) is a Gi-preferring CCKBR agonist. CCKBR agonist-2 effectively activates the CCKBR-Gi signaling pathway (EC50 = 0.27 nM), but has almost no activity on Gq and Gs signaling pathways. CCKBR agonist-2 shows no significant protective effect in the mouse Alzheimer's disease model, proving that the simple activation of the Gi signal pathway does not play a dominant role in the improvement of cognitive function .
loading...
    loading...
Cat. No.: HY-18882
CAS No.: 1357621-20-5
Target:  

p38 MAPK

Research Areas:  

Cancer

P38α-IN-11 (Compound 16c) is a p38α inhibitor with a KD value of 586 nM. P38α-IN-11 can be used for research on cervical cancer .
loading...
    loading...
Cat. No.: HY-19215
CAS No.: 149394-65-0
Synonyms: PNU-96988
Target:  

HIV HIV Protease

Research Areas:  

Infection

U-96988 (PNU-96988) is a non-peptide HIV-1 protease inhibitor with a Ki value of 38 nM. U-96988 is also effective against HIV-2 protease. U-96988 exhibits an IC50 for HIV-1IIIB of 5 μM. U-96988 can be used for research on HIV infection .
loading...
    loading...
Cat. No.: HY-179607
CAS No.: 2954281-30-0
Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

LUF8100 is a dual-target antagonist of CCR2/CCR5 with pKi values for CCR2 and CCR5 of 5.23 and 4.97 respectively. LUF8100 can be used for research on immune homeostasis and cancer .
loading...
    loading...
Cat. No.: HY-111103A
CAS No.: 2231440-94-9
Target:  

PAK

Research Areas:  

Cancer

CZh226 hydrochloride is a potent and selective PAK4 inhibitor with an IC50 of 18 nM, and its selectivity for PAK1 is 346 times. The oral bioavailability of CZh226 hydrochloride is poor, and it requires the use of the prodrug PAK4-IN-1 (HY-130628) to improve absorption and metabolic stability. CZh226 hydrochloride can be used for research on colorectal cancer and melanoma .
loading...
    loading...
Cat. No.: HY-179684
CAS No.: 2921670-99-5
PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC50 = 77.91 nM). PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine .
loading...
    loading...
Cat. No.: HY-180484
CAS No.: 2974454-59-4
Research Areas:  

Cancer

PKMYT1-IN-12 (Compound 4) is a selective inhibitor of PKMYT1, with an IC₅₀ of 2.6 nM. PKMYT1-IN-12 can effectively inhibit the phosphorylation of CDK1, with an IC₅₀ of 44 nM. PKMYT1-IN-12 is a target protein ligand that can be used for the synthesis of PROTAC D16-M1P2 (HY-180485) .
loading...
    loading...
Cat. No.: HY-184652
Target:  

LRRK2 JNK CaMK Casein Kinase

Research Areas:  

Neurological Disease

LRRK2/JNK3-IN-1 is a brain-penetrant multi-target inhibitor of LRRK2 (including G2019S mutant and wild-type) and JNK3, with enzymatic IC50 values of 3.90 nM against LRRK2 G2019S, 3.24 nM against wild-type LRRK2, and 22.1 nM against JNK3. LRRK2/JNK3-IN-1 displays favorable selectivity in a 97-kinase profiling screen, and also shows inhibitory activity against JNK1, JNK2, and MKNK2. LRRK2/JNK3-IN-1 can be used for the research of Parkinson's disease .
loading...
    loading...